What's in Optinose US Inc.'s pipeline?

Optinose US Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Optinose US Inc.'s portfolio?

Top competitors by shared drug class: Xiyuan Hospital of China Academy of Chinese Medical Sciences.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/optinose-us-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Optinose US Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optinose US Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
OPN-375	OPN-375	phase 3	5-HT4 receptor agonist	5-HT4 receptor	Gastroenterology

Therapeutic area mix

Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Xiyuan Hospital of China Academy of Chinese Medical Sciences · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Optinose US Inc.:

Cite this brief

Drug Landscape (2026). Optinose US Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/optinose-us-inc. Accessed 2026-06-10.